GILD

(Bloomberg) -- Kalshi Inc. is expanding in biotechnology by offering wagers on the outcomes of clinical trials and regulatory decisions, giving traders a more direct way to bet on key industry catalysts. Most Read from Bloomberg Thailand Scraps Plan to End Visa-Free Entry for Indian Tourists OpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI Companion CIA Says AI Drones Give Russian Troops Only 30 Minutes to Live Beckham’s IM8 Gets $1 Billion From General Catalyst for Growth OnePlus, Once Popular with Tech Fans, to Pull Out of US and Europe The prediction market platform says the move will allow investors to isolate binary events like drug approvals from a company’s overall stock performance. Kalshi launched 13 new biotech contracts last night in partnership with AI-powered intelligence firm AppliedXL, including bets on whether US regulators will approve medicines made by companies like Sanofi and Gilead Sciences Inc. Biotechnology is a highly speculative corner of the market that is prone to massive stock swings and much uncertainty. While Kalshi and rival Polymarket have offered some healthcare-related contracts in the past, this expansion fits into Kalshi’s ongoing effort to show that prediction markets can provide socially useful information, rather than just an outlet for sports gambling. Bloomberg reported Wednesday that Kalshi is evaluating whether to offer wagers on flight-cancellation rates at specific airports. While prediction markets are federally regulated under US law, the vast majority of their volume comes from sports contracts, which have been accused by states of violating gambling laws. Healthcare is so far a relatively small market for Kalshi. In the last week of June, the platform hosted $3.6 million of trading on all science and technology topics, while sports attracted $5.4 billion, according to user-compiled data from Dune Analytics. Drug development is often characterized by fragmented information, delayed disclosures and optimistic corporate messaging around trial results. Kalshi says data generated by prediction markets can provide clearer signals to investors about the likelihood of success, helping them make better decisions. Michael Selig, the chair of the Commodity Futures Trading Commission that regulates prediction markets, has also touted drug-trial contracts as a potential way for sick people in need of m...

Gilead Sciences Inc. (NASDAQ:GILD) ranks among the best set-it-and-forget-it stocks to buy right now. Cantor Fitzgerald restated an Overweight rating and a $155 price target for Gilead Sciences Inc. (NASDAQ:GILD) on June 9, following the company’s clinical research findings. Gilead Sciences Inc. (NASDAQ:GILD), in collaboration with Merck, revealed solid top-line results from the phase 3 ISLEND-1 and ISLEND-2 studies of weekly islatravir/lenacapavir for HIV medication. Additionally, the companies reported negative findings from the EVOKE-03 study comparing Trodelvy with Keytruda versus Keytruda monotherapy in patients with first-line PD-L1 non-small cell lung cancer. Moreover, on June 8, RBC Capital reaffirmed its $122 Sector Perform rating for Gilead Sciences Inc. (NASDAQ:GILD). The firm made remarks regarding the company’s position in the domain of in vivo CAR-T treatment. The firm added that in vivo CAR-T represents a possible risk to a sector that is estimated to account for 10-15% of Gilead’s potential revenue. According to RBC Capital, Gilead Sciences Inc. (NASDAQ:GILD) has begun to build promising technology in the field with differentiating features and a wide approach that incorporates current experience. Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years Disclosure: None. Follow Insider Monkey on Google News.

Since December 2025, Gilead Sciences has been in a holding pattern, posting a small return of 2.7% while floating around $124.73. The stock also fell short of the S&P 500’s 10.9% gain during that period. Given the weaker price action, is now a good time to buy GILD? Or should investors expect a bumpy road ahead? Find out in our full research report, it’s free. From its groundbreaking work in developing the first single-tablet regimens for HIV treatment, Gilead Sciences (NASDAQ:GILD) develops and markets innovative medicines for life-threatening diseases including HIV, viral hepatitis, COVID-19, and cancer. Adjusted operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses — everything from the cost of goods sold to advertising and wages. It’s also useful for comparing profitability across companies because it excludes non-recurring expenses, interest on debt, and taxes. Analyzing the trend in its profitability, Gilead Sciences’s adjusted operating margin rose by 19.7 percentage points over the last two years, as its sales growth gave it operating leverage. Its adjusted operating margin for the trailing 12 months was 45.6%. Free cash flow isn’t a prominently featured metric in company financials and earnings releases, but we think it’s telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king. Gilead Sciences has shown terrific cash profitability, enabling it to reinvest, return capital to investors, and stay ahead of the competition while maintaining an ample cushion. The company’s free cash flow margin was among the best in the healthcare sector, averaging an eye-popping 33% over the last five years. A company’s long-term performance is an indicator of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Unfortunately, Gilead Sciences’s 3.1% annualized revenue growth over the last five years was tepid. This wasn’t a great result compared to the rest of the healthcare sector, but there are still things to like about Gilead Sciences. Gilead Sciences’s merits more than compensate for its flaws. With its shares underperforming the market lately, the stock trades at $124.73 per share (or a forward price-to-sales ratio of 5.2×). Is now a good time to buy? See for yourself in our comprehe...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued quality stocks to invest in. On June 2, Gilead Sciences announced positive Phase 3 IDEAL trial results for Livdelzi (seladelpar) in patients with primary biliary cholangitis/PBC. The study showed statistically significant improvements in composite alkaline phosphatase/ALP normalization compared with placebo after 52 weeks. The trial evaluated patients with inadequately controlled PBC, including those with elevated ALP levels or intolerance to ursodeoxycholic acid/UDCA. Results demonstrated that a higher proportion of patients achieved sustained ALP normalization, with a safety profile consistent with previous studies and no new safety concerns identified. Gilead said the findings strengthen evidence supporting ALP normalization as a key treatment goal in PBC and expand understanding of Livdelzi’s clinical benefit across a broader patient population. The company also noted that full results will be presented at an upcoming medical congress and shared with regulatory authorities for further review. Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Disclosure: None. Follow Insider Monkey on Google News.

– Novel Investigational Combination Pairs Merck’s Islatravir, a Next-Generation Nucleoside Analog with Distinct Mechanisms of Action, Including Reverse Transcriptase Translocation Inhibition, with Gilead’s Lenacapavir, a First-in-Class Capsid Inhibitor that Disrupts HIV at Multiple Stages of its Lifecycle – – Islatravir/Lenacapavir has the Potential to be the First Approved Long-Acting Oral HIV Treatment Taken Once-Weekly – FOSTER CITY, Calif., & RAHWAY, N.J., June 08, 2026--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the primary efficacy endpoint at Week 48 was met in both the Phase 3 ISLEND-1 and ISLEND-2 trials with the investigational oral once-weekly single-tablet HIV treatment regimen of islatravir/lenacapavir. The ISLEND trials are evaluating the efficacy and safety of islatravir 2 mg/lenacapavir 300 mg (ISL/LEN) in people with HIV who are virologically suppressed and switched from BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) (ISLEND-1) or standard of care antiretroviral regimens (ISLEND-2). The safety profile of ISL/LEN was generally comparable to the comparator regimens studied in the ISLEND trials, and no new safety concerns were identified. Gilead and Merck plan to file the Phase 3 data from the ISLEND trials with regulatory authorities globally and submit the detailed findings for presentation at a future scientific congress. "Long-acting oral therapies represent a new wave of transformational innovation in HIV drug development, with the potential to reshape the landscape of care," said Jared Baeten, MD, PhD, Senior Vice President, Clinical Development, Virology Therapeutic Area Head, Gilead Sciences. "Innovative oral HIV treatment options that allow for less frequent dosing may make a meaningful difference in the lives of people living with the virus, potentially offering more flexibility and discretion." The primary efficacy endpoint of ISLEND-1 and ISLEND-2 was the percentage of participants with HIV-1 RNA levels ≥ 50 copies/mL at Week 48, defined by the FDA snapshot algorithm. In the double-blind ISLEND-1 trial, the once-weekly, single-tablet regimen of ISL/LEN was found to be statistically non-inferior to BIKTARVY. In the open-label ISLEND-2 trial, ISL/LEN was found to be statistically...

Gilead Sciences, Inc. GILD announced positive results from the late-stage IDEAL study in patients with primary biliary cholangitis (PBC). Results showed that Livdelzi (seladelpar) significantly increased the proportion of patients achieving normalization of alkaline phosphatase (ALP), an important marker of liver disease progression, compared with placebo after 52 weeks. The positive results were seen in patients with inadequately controlled PBC, characterized by ALP levels above the upper limit of normal (ULN) but below 1.67 times the ULN, despite treatment with ursodeoxycholic acid (UDCA), or in those unable to tolerate UDCA. Although this patient group is commonly seen in clinical practice, it has historically been underrepresented in randomized clinical trials. Livdelzi is an orally administered peroxisome proliferator-activated receptor delta (PPAR-δ) agonist. It is indicated for the treatment of PBC in combination with UDCA in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. IDEAL is a phase III, randomized, double-blind, placebo-controlled trial evaluating Livdelzi in adults with PBC whose disease remains inadequately controlled despite treatment with UDCA who are unable to tolerate UDCA. Eligible participants had ALP levels above the ULN but below 1.67 times the ULN. The study’s primary objective is to assess the efficacy of Livdelzi versus placebo at week 52 in achieving ALP normalization. The trial enrolled 96 adults aged 18 to 75 years. The safety findings from the IDEAL study were consistent with the established safety profile of Livdelzi observed in previous clinical trials, with no new safety signals or unexpected adverse events reported. PBC is a chronic autoimmune liver disorder characterized by damage to the bile ducts, affecting approximately 130,000 individuals in the United States. The condition occurs more frequently in women and, if left untreated, can lead to progressive liver damage, liver failure, and the eventual need for a liver transplant. The FDA approved Livdelzi for PBC under accelerated approval based on a reduction of ALP. Improvement in survival or prevention of liver decompensation events has not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Gilead intends to...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best inexpensive stocks to invest in right now. Gilead Sciences, Inc. (NASDAQ:GILD) announced on May 27 new results from a post hoc analysis that showed that Livdelzi® was associated with high and sustained rates of normalization of a key liver marker in people living with primary biliary cholangitis. The company reported that participants with increased ALP levels in an ongoing Phase 3 study experienced reductions in ALP after treatment, and the data showcase the potential role of Livdelzi in people with PBC who continually have elevated ALP despite prior treatment with first-line therapy. Gilead Sciences, Inc. (NASDAQ:GILD) stated that the findings are “highly relevant” for people living with PBC with inadequately controlled disease based on elevated ALP levels, as that is a population that is historically underrepresented in randomized clinical trials. The company would present the data at the European Association for the Study of the Liver (EASL) Congress 2026, held May 27–30 in Barcelona, Spain. Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19. Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow. Disclosure: None. Follow Insider Monkey on Google News.

Compugen Ltd. (NASDAQ:CGEN) shares jumped more than 18% in premarket trading on Monday after the biotechnology company reported first-quarter revenue ahead of analyst expectations, despite posting a slightly wider-than-expected quarterly loss. The clinical-stage cancer immunotherapy company reported a quarterly loss of $0.08 per share for the period ended March 31, missing analyst estimates that had projected a loss of $0.07 per share. Revenue came in at $2.2 million, exceeding consensus expectations of $1.63 million. However, quarterly revenue was down 4% compared with $2.3 million reported in the first quarter of 2025. Compugen said revenue during the quarter reflected recognition of portions of both the upfront payment and the IND milestone payment tied to its licensing agreement with Gilead. Despite the earnings miss, investors appeared encouraged by stronger-than-expected revenue and continued advancement across the company’s clinical development programs. Compugen said enrollment in its COM701 MAIA-ovarian study is continuing across all participating clinical sites in the United States, Israel and France. The company remains on schedule to conduct an interim analysis during the first quarter of 2027. “Q1 2026 reflects continued execution across all of our programs in line with our strategic priorities,” said Eran Ophir, president and chief executive of Compugen. “With enrollment progressing across all COM701 MAIA-ovarian trial sites, we remain on track for having the median progression-free survival at the interim analysis by Q1 2027, a key potential inflection point for COM701 as a maintenance therapy in a patient population with significant unmet medical need and no current standard of care.” Research and development expenses increased to $6.9 million from $5.8 million a year earlier, primarily driven by higher clinical trial spending related to the MAIA-ovarian program and increased drug supply costs. General and administrative expenses edged slightly lower to $2.3 million from $2.4 million. Compugen reported total cash, cash equivalents, short-term bank deposits and marketable securities of approximately $134.9 million as of March 31, 2026. The company said its current financial resources are expected to support operations through 2029 based on existing development plans. Compugen also noted that partner AstraZeneca is continuing development of ril...

Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs. On the company’s first-quarter earnings call, President and Chief Executive Officer Dr. Eran Ophir said 2026 is “shaping up to be a significant year” for Compugen as it advances COM701, its wholly owned antibody targeting PVRIG, and monitors progress on partnered assets with AstraZeneca and Gilead. → 3 Crucial Aerospace Component Makers That Analysts Love Compugen’s lead wholly owned clinical program, COM701, is being evaluated in the MAIA-ovarian adaptive platform trial as maintenance monotherapy compared with placebo in patients with relapsed platinum-sensitive ovarian cancer who responded to their most recent line of chemotherapy. Ophir said the company initiated the study based on prior data presented at ESMO, where pooled clinical data showed COM701, as monotherapy and in combinations, was well-tolerated and produced “consistent, durable responses” in heavily pretreated patients with platinum-resistant ovarian cancer. → 3 Stocks to Own If Gas Prices Keep Rising The company is now testing COM701 in an earlier ovarian cancer setting, with the rationale that patients may have lower tumor burden and a less compromised immune system, potentially improving the likelihood of benefit from COM701’s mechanism of action. Ophir said all clinical sites are open and enrolling across the United States, Israel and France. He said that gives the company confidence in its ability to complete enrollment on schedule for interim median progression-free survival data in the first quarter of 2027. → Peloton Stock Gives Back Gains After Upbeat Earnings Report Chief Medical Officer Dr. Michelle Mahler said during the question-and-answer session that Compugen is not currently commenting on specific enrollment numbers, but remains “on track” for the planned interim analysis. She said the study is stratified by second-line versus third-line treatment, not by PD-L1 status. Ophir added that prior clinical signals with COM701 have been seen in both PD-L1-positive and PD-L1-negative patients, saying PD-L1 stratification may not be the critical factor for the PVRIG-targeting approach. Mahler said t...

Gilead Sciences began 2026 with revenue and adjusted earnings per share both exceeding Wall Street expectations, reflecting strong commercial execution and demand across its core franchises. Management highlighted robust performance in the HIV segment, particularly from Biktarvy and the PrEP portfolio, as well as continued momentum in oncology with Trodelvy and rapid growth from newly launched products like Yes2Go. CEO Daniel O’Day pointed to disciplined financial management and recent product launches as central to the quarter’s performance, while CFO Andrew Dickinson emphasized that non-GAAP operating margins improved due to expense management and the expiration of certain royalties. Notably, management guided to a large negative adjusted EPS for the full year, driven by the impact of acquisition-related IPR&D charges, a key forward-looking disclosure. Is now the time to buy GILD? Find out in our full research report (it’s free). Revenue: $6.96 billion vs analyst estimates of $6.86 billion (4.4% year-on-year growth, 1.5% beat) Adjusted EPS: $2.03 vs analyst estimates of $1.91 (6.3% beat) Adjusted EBITDA: $4.2 billion vs analyst estimates of $3.56 billion (60.4% margin, 18.1% beat) The company lifted its revenue guidance for the full year to $30.2 billion at the midpoint from $29.8 billion, a 1.3% increase Management lowered its full-year Adjusted EPS guidance to -$0.85 at the midpoint, a 110% decrease Operating Margin: 37.2%, up from 33.5% in the same quarter last year Market Capitalization: $165.2 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Akash Tewari (Jefferies) asked about the value drivers of the Tubulis acquisition, especially in ovarian versus lung cancer. Chief Medical Officer Dietmar Berger emphasized the strong efficacy and safety profile in ovarian cancer, while CFO Andrew Dickinson confirmed ovarian cancer alone justifies the transaction, with lung cancer providing upside. Terence Flynn (Morgan Stanley) inquired about Yes2Go’s mix of naive versus switch patients and adherence assumptions. Chief Commercial Officer Johanna Mercier noted strong initial adoption, high coverage, and increasing...

– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule entry inhibitor candidate for chronic hepatitis delta virus; Phase 2 initiation anticipated Q4 2026 – SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results for the first quarter ended March 31, 2026, and recent highlights. “The first quarter reflected steady progress across our portfolio as we continue advancing our discovery and development programs,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “As we look ahead, we anticipate receiving Gilead’s development plan and budget for the herpesvirus program and will evaluate our cost and profit share opt-in decision by mid-2026 while continuing to advance ABI-6250 toward Phase 2 in hepatitis delta virus by year-end.” First Quarter 2026 and Recent Highlights Completed follow-up period for all participants in the Phase 1b portion of the studies for ABI-5366 and ABI-1179, reinforcing continued confidence in the safety and efficacy findings previously disclosed for both candidates Completed chronic toxicology studies for ABI-6250, establishing support for anticipated phase 2 doses Presented an oral presentation and three posters, including one late-breaker, highlighting interim Phase 1b data for ABI-5366 and ABI-1179 at the 2026 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in Munich, Germany Anticipated Milestones and Events By mid-2026, upon receipt of Gilead Sciences, Inc. (Gilead)’s development plan and budget for the helicase-primase inhibitor (HPI) program (ABI-5366 and ABI-1179) for recurrent genital herpes, Assembly Bio to determine whether to opt in to a 40% U.S. cost-profit share, in lieu of receiving U.S. milestones and royalties Initiation of a Phase 2 clinical study for ABI-6250 in participants with chronic hepatitis delta virus (HDV) infection expected in the fourth quarter of 2026 Upcoming Conferences European Association for the Study of the Liver (EASL) Congress: May 27-30, 2026 – Barcelona, Spain ABI-5366, ABI-1179 and ABI-6250 are investigational product candidate...

Gilead Sciences (GILD) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $1.89 per share. This compares to earnings of $1.81 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +7.68%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $1.83 per share when it actually produced earnings of $1.86, delivering a surprise of +1.64%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Gilead, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.96 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.95%. This compares to year-ago revenues of $6.67 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Gilead shares have added about 11.1% since the beginning of the year versus the S&P 500's gain of 7.6%. While Gilead has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Gilead was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank...